Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system

Because the presence of IgG paraprotein in the blood is clear cut, it makes IgG myeloma a more circumscribed disease than myeloma as a whole in which to study treatment efficacy, particularly relating to complete remission (CR).

[1]  M. Gore,et al.  A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results , 1998, British journal of haematology.

[2]  P. Bolufer,et al.  Prolonged molecular remission after PML/RARα-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft? , 1998, Leukemia.

[3]  H. Goldschmidt,et al.  High-dose chemotherapy in multiple myeloma. , 1997, Leukemia.

[4]  S. Singhal,et al.  Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment , 1997, Bone Marrow Transplantation.

[5]  R. Aster,et al.  Sensitivity to a Metabolite of Diclofenac as a Cause of Acute Immune Hemolytic Anemia , 1997 .

[6]  S. Singhal,et al.  Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients , 1997, Bone Marrow Transplantation.

[7]  S. Singhal,et al.  A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C‐VAMP) as induction treatment followed by autografting in previously untreated myeloma , 1997, British journal of haematology.

[8]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[9]  R. Kyle,et al.  Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 Years , 1996, British journal of haematology.

[10]  J. Goldman,et al.  Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. , 1996, Blood.

[11]  H. Sather,et al.  Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Singhal,et al.  Kinetics of paraprotein clearance after autografting for multiple myeloma. , 1995, Bone marrow transplantation.

[13]  A. Hagenbeek,et al.  Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  V. Diehl,et al.  Chronic lymphocytic leukemia with an interfollicular architecture: avoiding diagnostic confusion with monocytoid B-cell lymphoma. , 1995, Leukemia & lymphoma.

[15]  P. Ljungman,et al.  Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. , 1994, Leukemia & lymphoma.

[16]  E. Holmberg,et al.  Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients , 1994, European journal of haematology.

[17]  M. Gore,et al.  High-dose melphalan for multiple myeloma: long-term follow-up data. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Hickish,et al.  High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Gore,et al.  INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION , 1989, The Lancet.

[20]  S. Lakhani,et al.  Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. , 1988, British Journal of Cancer.

[21]  P. Selby,et al.  The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's hospital studies , 1988, Hematological oncology.

[22]  J. Cuzick,et al.  The prognostic value of serum , 2 microglobulin compared with other presentation features in myelomatosis ( A report to the Medical Research Council ' s Working Party on Leukaemia in Adults ) * , 2007 .

[23]  H. Karinkanta,et al.  An improved technique for immunofixation of electrophoretograms. , 1978, Clinical chemistry.

[24]  P. Wiernik.  Treatment of acute leukaemia in adults. , 1978, Clinics in haematology.

[25]  P. Riches,et al.  A cellulose acetate immunofixation technique. , 1978, Journal of immunological methods.

[26]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[27]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[28]  J. Burchenal,et al.  Treatment of acute leukemia in adults , 1975, Cancer.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .

[31]  B. Barlogie,et al.  Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.

[32]  S. Singhal,et al.  Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. , 1997, British Journal of Cancer.

[33]  S. Singhal,et al.  Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. , 1996, Leukemia & lymphoma.

[34]  B. Barlogie,et al.  Autologous and allogeneic transplants for multiple myeloma. , 1995, Seminars in hematology.

[35]  J. Hobbs.  Immunoglobulins in clinical chemistry. , 1971, Advances in clinical chemistry.

[36]  F. Hayhoe.  The treatment of acute leukaemia. , 1966, The Practitioner.

[37]  D.,et al.  Regression Models and Life-Tables , 2022 .